[PDF][PDF] The SS18-SSX oncoprotein hijacks KDM2B-PRC1. 1 to drive synovial sarcoma

A Banito, X Li, AN Laporte, JS Roe, F Sanchez-Vega… - Cancer cell, 2018 - cell.com
A Banito, X Li, AN Laporte, JS Roe, F Sanchez-Vega, CH Huang, AR Dancsok, K Hatzi
Cancer cell, 2018cell.com
Synovial sarcoma is an aggressive cancer invariably associated with a chromosomal
translocation involving genes encoding the SWI-SNF complex component SS18 and an SSX
(SSX1 or SSX2) transcriptional repressor. Using functional genomics, we identify KDM2B, a
histone demethylase and component of a non-canonical polycomb repressive complex 1
(PRC1. 1), as selectively required for sustaining synovial sarcoma cell transformation. SS18-
SSX1 physically interacts with PRC1. 1 and co-associates with SWI/SNF and KDM2B …
Summary
Synovial sarcoma is an aggressive cancer invariably associated with a chromosomal translocation involving genes encoding the SWI-SNF complex component SS18 and an SSX (SSX1 or SSX2) transcriptional repressor. Using functional genomics, we identify KDM2B, a histone demethylase and component of a non-canonical polycomb repressive complex 1 (PRC1.1), as selectively required for sustaining synovial sarcoma cell transformation. SS18-SSX1 physically interacts with PRC1.1 and co-associates with SWI/SNF and KDM2B complexes on unmethylated CpG islands. Via KDM2B, SS18-SSX1 binds and aberrantly activates expression of developmentally regulated genes otherwise targets of polycomb-mediated repression, which is restored upon KDM2B depletion, leading to irreversible mesenchymal differentiation. Thus, SS18-SSX1 deregulates developmental programs to drive transformation by hijacking a transcriptional repressive complex to aberrantly activate gene expression.
cell.com